Valuation: C4 Therapeutics, Inc.

Market Cap 340M 302M 280M 255M 481M 32.28B 489M 3.37B 1.32B 16.85B 1.28B 1.25B 53.71B P/E 2026 *
-3.25x
P/E 2027 * -2.93x
Enterprise Value 259M 230M 213M 194M 366M 24.57B 372M 2.56B 1.01B 12.82B 972M 951M 40.87B EV / Sales 2026 *
9.81x
EV / Sales 2027 * 10x
Free-Float
99.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+5.42%
1 week-5.39%
Current month-13.06%
1 month-12.27%
3 months-19.13%
6 months-3.18%
Current year+51.57%
1 week 2.59
Extreme 2.59
3.06
1 month 2.59
Extreme 2.59
3.45
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
48.75
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 01/10/2020
Director of Finance/CFO 49 17/09/2023
Chief Tech/Sci/R&D Officer 56 27/10/2024
Director TitleAgeSince
Director/Board Member 74 30/11/2015
Director/Board Member 55 13/09/2020
Director/Board Member 55 15/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Founder

3,662 0.0030%
01/10/26 Free

Director

4,618 0.0038%
18/09/26 Exercice

Chief Financial Officer

9,025 0.0073%
Change 5-day change 1-year change 3-year change Capi.($)
+5.42%-5.39%+13.98%+56.49% 340M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+6.83%+10.89%+79.30% 51.2B
+0.30%-0.46%-0.03%+61.89% 51.19B
-0.77%+0.85%+24.71%+41.60% 43.93B
+0.40%+5.78%+16.34%+133.60% 41.96B
+2.41%-6.50%+235.77%+525.34% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+2.21%+27.96%+28.00% 22.5B
Average +1.32%-1.12%+43.73%+105.51% 37.27B
Weighted average by Cap. +0.89%+0.03%+45.28%+112.05%

Financials

2026 *2027 *
Net sales 26.4M 23.47M 21.75M 19.79M 37.34M 2.51B 37.94M 261M 103M 1.31B 99.08M 96.97M 4.17B 22.29M 19.81M 18.36M 16.71M 31.52M 2.12B 32.03M 221M 86.53M 1.1B 83.64M 81.86M 3.52B
Net income -113M -101M -93.19M -84.78M -160M -10.73B -163M -1.12B -439M -5.6B -424M -415M -17.86B -146M -130M -120M -109M -206M -13.85B -210M -1.44B -567M -7.23B -548M -536M -23.04B
Net Debt -81.29M -72.26M -66.97M -60.93M -115M -7.72B -117M -805M -316M -4.03B -305M -299M -12.83B -117M -104M -96.52M -87.82M -166M -11.12B -168M -1.16B -455M -5.8B -440M -430M -18.5B
Projected Income Statement - Annual - C4 Therapeutics, Inc.
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
19/10/26 US$2.895 +4.70% 789,378
16/10/26 US$2.765 -0.54% 2,359,351
15/10/26 US$2.780 +6.51% 3,275,294
14/10/26 US$2.610 -6.12% 3,099,942
13/10/26 US$2.780 -9.15% 3,821,394
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - C4 Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.765USD
Average target price
12.86USD
Spread / Average Target
+365.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - C4 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CCCC Stock